Helius Medical pre-announces Q3 revenue $140-150K; cash runway into Q2 2024

Solana Co

2023-Q3 EPS reported -$13.60 revenue$510,000

Expects Q3 revenue $140-150K, down after PTAP ended June 30, 2023.
Cash, equivalents and warrant proceeds ~$7.0M, extending runway into Q2 2024.
Cash used in ops Q3: $2.4-2.5M; first nine months: $8.3-8.4M, reflecting cost management.
Full Q3 results to be released Nov 9, 2023 after market close.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Solana Co reported the quarter ended September 30, 2023 results: revenue $140 - $150 thousand. Guidance initiated.

Period: the quarter ended September 30, 2023
Revenue: $140 - $150 thousand
Guidance: initiated
Result: preliminary results

Exact text from the filing

Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Solana Co filing history →

Source: SEC EDGAR

accession 0001558370-23-017464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.